MBRX
Moleculin Biotech, Inc.
$2.47
-0.80%
2026-05-08
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Key Fundamentals
Forward P/E
-0.02
EPS (TTM)
$-28.42
ROE
-256.0%
Profit Margin
0.0%
Debt/Equity
2.39
Price/Book
0.52
Beta
1.74
Market Cap
$13.1M
Avg Volume (10D)
81K
Recent Breakout Signals
No recent breakout signals detected for MBRX.
Recent Price Range (60 Days)
60D High
$5.30
60D Low
$1.79
Avg Volume
170K
Latest Close
$2.47
Get breakout alerts for MBRX
Sign up for Breakout Scanner to receive daily notifications when MBRX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Moleculin Biotech, Inc. (MBRX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MBRX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MBRX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.